Alto Neuroscience Inc
NYSE:ANRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Alto Neuroscience Inc
Revenue
Alto Neuroscience Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Alto Neuroscience Inc
NYSE:ANRO
|
Revenue
0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Revenue
$27.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
|
Schlumberger NV
NYSE:SLB
|
Revenue
$35.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
0%
|
|
|
Halliburton Co
NYSE:HAL
|
Revenue
$22.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
1%
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Revenue
$2.2B
|
CAGR 3-Years
56%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Revenue
$2.2B
|
CAGR 3-Years
49%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
Alto Neuroscience Inc
Glance View
Alto Neuroscience Inc is a US-based company operating in industry. The company is headquartered in Los Altos, California. The company went IPO on 2024-02-02. Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
See Also
What is Alto Neuroscience Inc's Revenue?
Revenue
0
Based on the financial report for Dec 31, 2024, Alto Neuroscience Inc's Revenue amounts to 0 .
